"Prediabetes": Are There Problems With This Label? No, We Need Heightened Awareness of This Condition!

被引:38
作者
Cefalu, William T. [1 ]
机构
[1] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA
基金
美国国家卫生研究院;
关键词
IMPAIRED GLUCOSE-TOLERANCE; ACTIVITY PROMOTION PROGRAMS; FASTING PLASMA-GLUCOSE; ATHEROSCLEROSIS RISK; DIABETES PREVENTION; COMBINED DIET; FOLLOW-UP; DISEASE; PEOPLE; ASSOCIATION;
D O I
10.2337/dc16-1143
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The category of prediabetes defined by the American Diabetes Association comprises a range of intermediate hyperglycemia based on fasting or 2-h postload glucose or on HbA(1c). Over the recent past, the cut points identifying this stage have changed, i.e., a lower fasting glucose level is used. On one hand, it can be argued that the change to a lower cut point identifies a group of individuals still at higher risk and provides heightened awareness for a condition associated with higher risk for cardiovascular disease. In addition, identification of individuals at this stage may represent a chance of earlier intervention in the disease. However, the argument against this definition of prediabetes is that it disguises the differences in the three subcategories and creates problems in interpreting observations on interventions and outcomes. In addition, it can be argued that the enormous numbers of people identified with the criteria far exceeds the capacity of health care systems to respond through individual care, particularly without evidence that interventions benefit any category other than impaired glucose tolerance. Thus, there does not appear to be consensus on the definition using the cut points identified. Controversy also remains as to whether there are glycemic metrics beyond HbA(1c) that can be used in addition to HbA(1c) to help assess risk of an individual developing diabetes complications. Given the current controversy, a Point-Counterpoint debate on this issue is provided herein. In the preceding point narrative, Dr. Yudkin provides his argument that there are significant problems with this label. In the counterpoint narrative below, Dr. Cefalu argues that the cut points are appropriate and do provide useful and important information in trying to reduce the future burden of diabetes.William T. CefaluEditor in Chief, Diabetes Care
引用
收藏
页码:1472 / 1477
页数:6
相关论文
共 28 条
[1]   Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose [J].
Abdul-Ghani, MA ;
Tripathy, D ;
DeFronzo, RA .
DIABETES CARE, 2006, 29 (05) :1130-1139
[2]   11. Children and Adolescents [J].
不详 .
DIABETES CARE, 2016, 39 :S86-S93
[3]   Incidence of Diabetes and Prediabetes and Predictors of Progression Among Asian Indians: 10-Year Follow-up of the Chennai Urban Rural Epidemiology Study (CURES) [J].
Anjana, Ranjit Mohan ;
Rani, Coimbatore Subramanian Shanthi ;
Deepa, Mohan ;
Pradeepa, Rajendra ;
Sudha, Vasudevan ;
Nair, Haridas Divya ;
Lakshmipriya, Nagarajan ;
Subhashini, Sivasankaran ;
Binu, Valsalakumari Sreekumarannair ;
Unnikrishnan, Ranjit ;
Mohan, Viswanathan .
DIABETES CARE, 2015, 38 (08) :1441-1448
[4]  
[Anonymous], 2015, IDF Diabetes Atlas, V7th
[5]   Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force [J].
Balk, Ethan M. ;
Earley, Amy ;
Raman, Gowri ;
Avendano, Esther A. ;
Pittas, Anastassios G. ;
Remington, Patrick L. .
ANNALS OF INTERNAL MEDICINE, 2015, 163 (06) :437-+
[6]   Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum [J].
Cefalu, William T. ;
Buse, John B. ;
Tuomilehto, Jaakko ;
Fleming, G. Alexander ;
Ferrannini, Ele ;
Gerstein, Hertzel C. ;
Bennett, Peter H. ;
Ramachandran, Ambady ;
Raz, Itamar ;
Rosenstock, Julio ;
Kahn, Steven E. .
DIABETES CARE, 2016, 39 (07) :1186-1201
[7]   Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04) :486-494
[8]   Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: The Ely study 1990-2000 [J].
Forouhi, N. G. ;
Luan, J. ;
Hennings, S. ;
Wareham, N. J. .
DIABETIC MEDICINE, 2007, 24 (02) :200-207
[9]   Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies [J].
Gerstein, Hertzel C. ;
Santaguida, Pasqualina ;
Raina, Parminder ;
Morrison, Katherine M. ;
Balion, Cynthia ;
Hunt, Dereck ;
Yazdi, Hossein ;
Booker, Lynda .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 78 (03) :305-312
[10]   Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study [J].
Gong, Q. ;
Gregg, E. W. ;
Wang, J. ;
An, Y. ;
Zhang, P. ;
Yang, W. ;
Li, H. ;
Li, H. ;
Jiang, Y. ;
Shuai, Y. ;
Zhang, B. ;
Zhang, J. ;
Gerzoff, R. B. ;
Roglic, G. ;
Hu, Y. ;
Li, G. ;
Bennett, P. H. .
DIABETOLOGIA, 2011, 54 (02) :300-307